Ann Clin Microbiol 2024;27(4):231-244. Candida and candidemia in Korea
| Candida species | C. albicans | C. tropicalis | C. parapsilosis | C. glabrata | C. auris |
|---|---|---|---|---|---|
| Collection period of isolates | 2006–2021 | 2003–2013 | 2005–2016 | 2008–2018 | 1996–2022 |
| Number of hospitals | 10 | 8 | 8 | 19 | 13 |
| Number of isolates | 26 BSI (14 FNS and 12 FS) isolates | 9 FNS, 12 FS (MIC, 1–2 µg/ml), and 14 control (MIC, 0.125–0.5 µg/ml) isolates | 67 BSI (47 FR and 20 FS) isolates | 278 BSI (66 FR and 212 F-SDD) isolates | 104 (96 clade II, and 8 clade I) isolates |
| Genes studied | Sequencing of ERG11, TAC1, MRR1, and UPC2 | Quantitation of CDR1, MDR1, and ERG11 expression, and sequencing of the ERG11 and UPC2 genes | Sequencing of ERG11, TAC1, MRR1, and UPC2 | Sequencing of pleiotropic drug resistance transcription factor (PDR1) | Sequencing of ERG11, TAC1A, and TAC1B |
| Results | Erg11p and Tac1p AASs are likely to contribute to FR in C. albicans BSI isolates in Korea | The majority of FNS C. tropicalis isolates show overexpression of CDR1, MDR1, and ERG11 genes | Majority (63.8%) of the C. parapsilosis FR isolates exhibit the Y132F substitution in Erg11p | Most FR BSI isolates of C. glabrata in Korea harbor FR-specific Pdr1p AAS | Tac1Bp AASs may be the predominant fluconazole resistance mechanism in clade II Korean isolates of C. auris |
| Year of publication | 2023 | 2016 | 2018 | 2021 | 2023 |
| References | [16] | [17] | [18] | [19] | [20] |
Abbreviations: BSI, bloodstream infection; FNS, fluconazole non-susceptible; FS, fluconazole susceptible; F-SDD, fluconazole susceptible dose-dependent; FR, fluconazole resistant; MIC, minimal inhibitory concentration; AAS, amino acid substitution.